Excellent
Aligned
Patient Risk:
Low
Summary
The evaluated claim is directly supported by the provided FDA label text for atorvastatin regarding increased myopathy/rhabdomyolysis risk with cyclosporine or strong CYP3A4 inhibitors (including clarithromycin, itraconazole, and HIV protease inhibitors).
Category Scores
Accurate Statements
Concomitant use of atorvastatin with cyclosporine or strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.
Supported in 5.1 (Skeletal Muscle): concomitant use of higher doses of atorvastatin with cyclosporine and strong CYP3A4 inhibitors increases risk of myopathy/rhabdomyolysis. Also supported in 7 (Drug Interactions): risk of myopathy increased with concurrent administration of cyclosporine or strong CYP3A4 inhibitors such as clarithromycin, HIV protease inhibitors, and itraconazole.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim accurately reflects labeled increased risk associated with the specified concomitant drugs.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement